
GUTS Stock Forecast & Price Target
GUTS Analyst Ratings
Bulls say
Fractyl Health is a clinical stage metabolic therapeutics company focused on developing novel treatments for obesity and type 2 diabetes. Their lead product, the Revita DMR system, has shown promising results in reducing weight regain after discontinuing GLP-1 therapy, with a statistically significant dose-response relationship observed between ablation length and weight maintenance. The company's strong execution in clinical trials and positive feedback from the FDA regarding their filing pathway also position them well for potential success in the market.
Bears say
Fractyl Health is a clinical stage metabolic therapeutics company with promising candidates designed to prevent and revert obesity and type 2 diabetes. However, the company's small sample sizes and short follow-up periods may not provide enough evidence of long-term efficacy, and there are standard industry risks that could impact their success. Additionally, the company's financial outlook may be hindered by high discount rates and potential challenges with financing, reimbursement, and commercialization.
This aggregate rating is based on analysts' research of Fractyl Health Inc and is not a guaranteed prediction by Public.com or investment advice.
GUTS Analyst Forecast & Price Prediction
Start investing in GUTS
Order type
Buy in
Order amount
Est. shares
0 shares